10-Q: ProKidney Corp. Reports Third Quarter 2024 Financial Results and Provides Clinical Trial Update

ProKidney Corp. reports its financial results for the third quarter of 2024, including a net loss, and provides an update on its clinical trial strategy for rilparencel.

Summary

• ProKidney Corp. reported a net loss of $17.9 million for the three months ended September 30, 2024, compared to a net loss of $10.9 million for the same period in 2023.
• The company's research and development expenses were $31.2 million for the quarter, a decrease from $32.1 million in the prior year.
• General and administrative expenses increased to $17.7 million from $14.4 million in the same quarter of the previous year, including a $5.3 million impairment charge related to a facility.
• For the nine months ended September 30, 2024, the net loss was $39.9 million, compared to $29.7 million for the same period in 2023.
• The company's cash and cash equivalents totaled $108.0 million as of September 30, 2024, up from $60.6 million at the end of 2023.
• Marketable securities were valued at $298.7 million as of September 30, 2024, slightly down from $302.3 million at the end of 2023.
• ProKidney has discontinued its PROACT 2 trial and will focus on the PROACT 1 trial for potential FDA approval of rilparencel.
• The company believes rilparencel is eligible for an expedited approval pathway based on the ongoing Phase 3 PROACT 1 trial.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made strategic decisions to streamline its clinical trial process and has received positive feedback from the FDA, it also reports increased losses and expenses. The need for additional funding and the inherent risks of drug development temper the positive aspects.

Positives

• Cash and cash equivalents increased to $108.0 million, providing financial stability.
• The FDA has confirmed that the PROACT 1 trial could be sufficient for a potential BLA submission.
• The FDA has confirmed that the accelerated approval pathway is available to rilparencel.
• The company has streamlined its clinical trial strategy by discontinuing the PROACT 2 trial.

Negatives

• The company reported a net loss of $17.9 million for the quarter and $39.9 million for the nine months ended September 30, 2024.
• General and administrative expenses increased, including a $5.3 million impairment charge related to a facility.
• The company has incurred significant operating losses and negative cash flows since its inception.

Risks

• The company has not generated any revenue since its inception and does not expect to generate revenue from product sales in the near future.
• The company's product candidates may not achieve commercial success, even if approved.
• The company will need substantial additional funding to support its continuing operations and pursue its growth strategy.
• The company's ability to raise additional funds may be adversely impacted by potential worsening global economic conditions.
• The company's clinical trials may experience delays or may not be successful.
• The company may not obtain regulatory approval for its product candidates.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to fund operations into mid-2026. They anticipate increased expenses as they continue clinical development, seek regulatory approvals, and expand operations. The company will need substantial additional funding to support its continuing operations and pursue its growth strategy.

Management Comments

• Management believes rilparencel is eligible for initial FDA approval under an expedited approval pathway based upon successful completion of the ongoing Phase 3 REGEN-006 (PROACT 1) trial.
• The FDA confirmed that PROACT 1 could be sufficient to support a potential Biologics License Application (BLA) submission.
• The FDA confirmed that the accelerated approval pathway is available to rilparencel and that the Company could consider eGFR slope as a surrogate endpoint for accelerated approval.

Industry Context

The company is focused on developing a cell therapy for chronic kidney disease, a significant unmet medical need. The discontinuation of the PROACT 2 trial and focus on the PROACT 1 trial reflects a strategic shift to expedite the regulatory approval process in the U.S. The company's engagement with the FDA and the potential for accelerated approval highlight the importance of innovative therapies in this space.

Comparison to Industry Standards

• ProKidney's focus on autologous cell therapy for kidney disease is a novel approach compared to traditional treatments like dialysis and transplantation.
• Companies like Vertex Pharmaceuticals and Travere Therapeutics are also developing treatments for kidney diseases, but their approaches differ from ProKidney's cell therapy.
• The company's decision to discontinue PROACT 2 and focus on PROACT 1 is a strategic move to potentially accelerate the approval process, which is a common strategy in the biotech industry.
• The company's cash burn rate and operating losses are typical for a clinical-stage biotech company, but the company's cash runway into mid-2026 is a positive sign.
• The company's engagement with the FDA and the potential for accelerated approval are positive developments that could differentiate it from competitors.

Related Party Transactions

• The company has consulting services agreements with Nefro Health, an Irish partnership controlled and majority-owned by Mr. Pablo Legorreta, a director of the Company.
• The company is party to a tax receivable agreement with a related party which provides for the payment by the Company to holders of PKLP prior to the Closing (Closing ProKidney Unitholders) of 85 % of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes.

Stakeholder Impact

• Shareholders may be concerned about the company's increasing losses and the need for additional funding.
• Employees may be affected by the company's strategic shifts and potential cost-cutting measures.
• Patients with chronic kidney disease may benefit from the company's development of rilparencel.
• Creditors and suppliers may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to engage with the FDA to further define the details supporting the accelerated approval pathway for rilparencel.
• The company will continue to enroll patients in the PROACT 1 trial.
• The company will continue to seek additional funding to support its operations and growth strategy.

Key Dates

Keywords

rilparencel, chronic kidney disease, CKD, clinical trial, FDA, biotechnology, cell therapy, PROACT 1, PROACT 2, net loss, financial results, regenerative medicine, RMAT, eGFR